Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen Sensitivity through BECN1 and Promotes an Autophagy-Associated Necrosis by Crawford, Anatasha C. et al.
Co-Inhibition of BCL-W and BCL2 Restores Antiestrogen
Sensitivity through BECN1 and Promotes an
Autophagy-Associated Necrosis
Anatasha C. Crawford, Rebecca B. Riggins, Ayesha N. Shajahan, Alan Zwart, Robert Clarke*
Lombardi Comprehensive Cancer Center and Department of Oncology, School of Medicine, Georgetown University, Washington, District of Columbia, United States of
America
Abstract
BCL2 family members affect cell fate decisions in breast cancer but the role of BCL-W (BCL2L2) is unknown. We now show the
integrated roles of the antiapoptotic BCL-W and BCL2 in affecting responsiveness to the antiestrogen ICI 182,780 (ICI;
Fulvestrant Faslodex), using both molecular (siRNA; shRNA) and pharmacologic (YC137) approaches in three breast cancer
variants; MCF-7/LCC1 (ICI sensitive), MCF-7/LCC9 (ICI resistant), and LY2 (ICI resistant). YC137 inhibits BCL-W and BCL2 and
restores ICI sensitivity in resistant cells. Co-inhibition of BCL-W and BCL2 is both necessary and sufficient to restore sensitivity to
ICI, and explains mechanistically the action of YC137. These data implicate functional cooperation and/or redundancy in
signaling between BCL-W and BCL2,and suggest that broad BCL2 family member inhibitors will have greatertherapeutic value
than targeting only individual proteins. Whereas ICI sensitive MCF-7/LCC1 cells undergo increased apoptosis in response to ICI
following BCL-W6BCL2 co-inhibition, the consequent resensitization of resistant MCF-7/LCC9 and LY2 cells reflects increases in
autophagy (LC3 cleavage; p62/SQSTM1 expression) and necrosis but not apoptosis or cell cycle arrest. Thus, de novo sensitive
cells and resensitized resistant cells die through different mechanisms. Following BCL-W+BCL2 co-inhibition, suppression of
functional autophagy by 3-methyladenine or BECN1 shRNA reduces ICI-induced necrosis but restores the ability of resistant
cells to die through apoptosis. These data demonstrate the plasticity of cell fate mechanisms in breast cancer cells in the
context of antiestrogen responsiveness. Restoration of ICI sensitivity in resistant cells appears to occur through an increase in
autophagy-associated necrosis. BCL-W, BCL2, and BECN1 integrate important functions in determining antiestrogen
responsiveness, and the presence of functional autophagy may influence the balance between apoptosis and necrosis.
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Introduction
Approximately 70% of all newly diagnosed breast cancers
express estrogen receptor-alpha (ER) [1], many of which are
sensitive to antiestrogens. The steroidal antiestrogen ICI 182,780
(ICI; Faslodex, Fulvestrant) is a selective ER downregulator
(SERD) that acts as an ER antagonist and enhances ubiquitin-
mediated ER degradation. ICI is an effective second-line
treatment for TAM resistant, ER-positive (ER+) tumors, and is
as effective as some aromatase inhibitors [2,3]. One limitation of
antiestrogen therapy is the prevalence of de novo and acquired
resistance in breast cancer. Acquired antiestrogen resistance
occurs when a tumor has an initially beneficial response to
antiestrogen treatment but the remaining tumor cells stop
responding [4,5]. We report the roles of BCL2L2 (BCL-W),
BCL2, and Beclin-1 (BECN1) in affecting responsiveness to ICI-
resistance, and describe how anti-apoptotic BCL2 family members
are involved in determining breast cancer cell fate.
BCL2 family proteins are essential regulators of apoptosis.
BCL2 and BCL-W are both antiapoptotic members of this family.
BCL-W maintains cell viability by preventing mitochondrial
membrane depolarization and caspase activation [6]. BCL-W
acts by binding to pro-apoptotic BCL2 family members and
preventing mitochondria-mediated apoptosis [7]. Overexpression
of BCL-W can prevent cell death [6] but its role(s) in affecting
breast cancer cell fate decisions or antiestrogen responsiveness is
unknown. BCL2 also blocks the induction of apoptosis by
inhibiting the activation of pro-apoptotic family members such
as BAX and preventing mitochondrial membrane depolarization
[8,9]. Overexpression of BCL2 is a potential mediator of resistance
to several chemotherapeutic drugs [10].
BCL2 family members also play essential roles in autophagy
(macroautophagy), a process characterized by the presence of
autophagosomes that engulf damaged organelles for subsequent
lysosomal degradation. Several anti-apoptotic BCL2 family mem-
bers inhibit the activity of BECN1 [11], a key regulator of
autophagy [12] that binds to PIK3C3 to facilitate autophagosome
production [13]. However, the precise relationships between
apoptosis and autophagy are unclear. Apoptosis or autophagy can
each lead to cell death, but in some cellular contexts autophagy is a
pro-survival process, for example, in the face of nutrient deprivation
[11]. While autophagy can contribute to TAM resistance in some
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antiestrogens is unknown. In ER+ MCF-7 breast cancer cells
treated with camptothecin, autophagy prolongs survival and delays
apoptosis [17]. In marked contrast, autophagy promotes apoptosis
in MCF-7 cells treated with the cytotoxic diterpenoid oridonin,
where an inhibition of autophagy increases cell survival [18].
We determined whether BCL-W and BCL2 regulate ICI
response in human breast cancer cells, and whether any effects
involve changes in apoptosis and/or BECN1-associated autoph-
agy. We used three estrogen-independent cell lines: MCF-7/
LCC1 (ICI sensitive) [19], and LY2 and MCF-7/LCC9 cells that
are crossresistant to TAM and ICI [20,21]. We show that co-
inhibition of BCL-W and BCL2 restores sensitivity to the growth-
inhibitory effects of ICI in both MCF-7/LCC9 and LY2 cells. In
re-sensitized cells, ICI treatment increases the levels of autophagy
and necrosis but has no effect on apoptosis. Inhibition of
autophagy by 3-methyladenine (3MA) or BECN1 shRNA under
these conditions reduces necrosis and increases apoptosis. Thus,
restoration of ICI sensitivity with BCL-W+BCL2 inhibition
appears to occur through increasing an autophagy-associated
necrotic cell death. Finally, we show that co-inhibiting BCL-W
and BCL2 improves ICI sensitivity in antiestrogen-sensitive cells
by increasing apoptosis. Therefore, BCL-W, BCL2, and BECN1
integrate central functions in determining ICI responsiveness likely
by regulating functional autophagy to dictate the balance between
apoptotic and necrotic cell death.
Results
We measured endogenous BCL-W and BCL2 expression in
control and ICItreated resistant and sensitivecells.BCL2expression
was significantly higher in ethanol control and ICI treated (resistant)
MCF-7/LCC9 cells when compared to (sensitive) MCF-7/LCC1
cells (Figure 1A; ANOVA p=0.002). BCL-W expression was lower
in MCF-7/LCC1 cells after 24 hr of ICI treatment and increased in
both sensitive and resistant cells after 72 hr of ICI treatment.
However, the levels in resistant cells remained higher than in
sensitive cells (Figure 1B; ANOVA p=0.004;).
To determine if BCL2 transcription is regulated in antiestrogen-
resistant cells, we measured basal BCL2 promoter activity using a
BCL2-luciferase promoter-reporter assay. Basal BCL2 promoter
activity was increased 14-fold in MCF-7/LCC9 cells (Figure S1;
Figure 1. Increased expression of BCL-W and BCL2 in MCF-7/LCC9 cells. Whole cell lysates were subjected to Western blot analysis with a
specific BCL2 or BCL-W antibody. (A) Bars represent the mean6SE of the relative BCL2:actin ratio (normalized to control cells) for three independent
experiments. Inset, a representative blot.( B) Bars represent the mean6SE of the relative BCL-W:actin ratio (normalized to control cells) for three
independent experiments. Inset, a representative blot.
doi:10.1371/journal.pone.0008604.g001
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the transcriptional regulation of basal BCL2 expression is altered
in MCF-7/LCC9 cells.
YC137 Restores ICI 182,780 Sensitivity by Increasing
Necrotic but Not Apoptotic Cell Death in Antiestrogen
Resistant Cells
We hypothesized that if the expression of pro-survival BCL2
family members is responsible for the resistance phenotype its
inhibition should restore antiestrogen sensitivity. We first tested this
hypothesis using the small molecule BCL2 inhibitor YC137 [22].
MCF-7/LCC1 and MCF-7/LCC9 cells were treated with YC137
(400 nmol/L) and ICI (20 nmol/L and 500 nmol/L) for 7-days.
Total cell number was significantly decreased after treatment with
both concentrations of ICI and/or YC137 in MCF-7/LCC1 cells
(ANOVA p,0.001; Fig. 2A). RI=2.56 (20 nmol/L ICI) and
RI=1.23 (500 nmol/L ICI) suggest a strong synergistic interaction
between 20 nmol/L ICI and YC137; the weaker interaction
between 500 nmol/L ICI and YC137 reflects the high potency of
500 nmol/L ICI alone in sensitive cells. In resistant cells, neither ICI
nor YC137 alone affected cell proliferation, whereas total cell
number decreased after YC137+ICI treatment (Figure 2A;A N -
OVA p=0.001) indicating a restoration of ICI sensitivity; RI=1.56
for the YC137+ICI treatment implies a synergistic interaction.
To determine the effect of BCL-W and BCL2 inhibition in
sensitive cells, MCF-7/LCC1 cells were treated with increasing
Figure 2. BCL-W and BCL2 inhibition increases sensitivity to ICI 182,780 and increases necrosis in MCF-7/LCC9 cells. (A) Cells were
treated with YC137 and/or ICI for 7-days. Bars represent the mean6SE of relative cell proliferation (normalized to EtOH treated controls) for a single
representative experiment performed in triplicate. (B) Cells were treated and stained with propidium iodide (PI). Bars represent the mean6SE of
relative PI staining (normalized to control EtOH treated cells) for three independent experiments. (C) Cells were transfected with siRNA and stained
with PI. Inset, a representative blot showing BCL-W and BCL2 siRNA knockdown.
doi:10.1371/journal.pone.0008604.g002
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effect; however, cell proliferation decreased significantly after 7-
days (Figure S2A; ANOVA p,0.001). After 5-days of
YC137+ICI treatment, YC137 further decreased cell proliferation
after treatment with ICI (Figure S2B; ANOVA p,0.001).
Results with 20 nM ICI are included in Fig. 2A for comparison.
To determine if YC137 increases apoptosis, MCF-7/LCC1 and
MCF-7/LCC9 cells were treated with YC137+ICI for 48 hr. Cell
fate was evaluated by measuring FITC-Annexin V (apoptosis) and
propidium iodide (PI) staining (to measure necrosis; not to detect
the sub-G1 peak) by FACS. In contrast to MCF-7/LCC1 cells,
treatment of MCF-7/LCC9 cells with YC137 or ICI only, or
YC137+ICI did not induce apoptosis (not shown). However, in
MCF-7/LCC9 cells treated with YC137+ICI a significant increase
in PI staining was observed (Figure 2B; p=0.036).
Whether the effects of YC137 are driven by inhibition of BCL-
W, BCL2, or inhibition of both proteins is required, is unknown.
To determine the effects of specific BCL2 family members on the
changes in cell death seen with YC137 treated cells, BCL-W and
BCL2 siRNA were used individually or concurrently to inhibit
their expression. Knockdown of either BCL-W or BCL2
individually or in combination in MCF-7/LCC9 cells does not
result in increased apoptosis when combined with ICI treatment in
resistant cells (not shown). However, we detected a significant
increase in PI staining after BCL-W6BCL2 knockdown and ICI
treatment (Figure 2C;p ,0.05), the greatest effect was seen when
both BCL-W and BCL2 are co-inhibited (Figure 2C;p ,0.05).
To confirm these observations morphologically, cells were treated
for 48 hr prior to staining with an acridine orange/ethidium
bromide solution and examined by fluorescence microscopy.
Images of viable cells (large, green nuclei), apoptotic cells
(condensed, green nuclei), late apoptotic cells (condensed red
nuclei), and necrotic cells (large, red-orange nuclei) were captured.
The greatest proportion of necrotic cells is seen with YC137+ICI
treatment (data not shown). These data show that BCL-W+BCL2
co-inhibition in ICI treated antiestrogen resistant cells most
strongly increases necrosis without significantly altering the rate
of apoptosis, while inhibition of BCL2 or BCL-W alone is not
sufficient.
ICI 182,780 Treatment Combined with BCL2 and BCL-W
Inhibition Increases Autophagy in Resistant Cells
During autophagy LC3 is cleaved to form LC3I and LC3II,
whereas p62/SQSTM1 binds to LC3 and is degraded [23]. To
determine if YC137 treatment acts by increasing autophagy, as
might be expected from its inhibition of BCL2 [24], cells were
treated with YC137 and/or ICI and examined for LC3 cleavage
and p62/SQSTM1 expression by Western blotting. In MCF-7/
LCC9 cells, there was a significant increase in LC3II expression
after YC137+ICI treatment when compared to ethanol treated
controls and MCF-7/LCC1 cells (Figure 3A; ANOVA p,0.001).
LC3II expression in the combination-treated cells was also
significantly higher than in cells treated with either YC137 or
ICI alone (Figure 3A; ANOVA p,0.001). Consistent with the
predicted increase in autophagy, p62/SQSTM1 expression was
downregulated in MCF-7/LCC9 cells treated with YC137 or
YC137+ICI; expression in the combination treated cells was
significantly lower than in cells treated with YC137 or ICI alone
(Figure 3B; ANOVA p,0.024). This decrease in p62/SQSTM1
expression was also observed in YC137+ICI treated MCF-7/
LCC1 cells (Figure 3B; ANOVA p,0.024). To determine if
BCL2+BCL-W knockdown produces the same effect as YC137,
MCF-7/LCC9 cells were transfected with both BCL2 and BCL-W
siRNAs and treated with ICI. Consistent with the effects of
YC137, BCL-W and BCL2 co-inhibition significantly increased
LC3II expression after ICI treatment (Figure 3C;p ,0.05).
Combined Inhibition of BCL2, BCL-W, and Autophagy (by
3MA) Increases Apoptosis and Decreases Necrosis
To investigate the functional role of autophagy after BCL-W
and BCL2 co-inhibition, MCF-7/LCC9 cells were treated
with the autophagy inhibitor 3MA (350 mmol/L) in combination
with ICI and YC137. Cell number was significantly decreased
in 3MA+ICI+YC137 co-treated cells (Figure 4A;A N O V A
p,0.001). However, treatment with 3MA+ICI+YC137 did not
decrease further MCF-7/LCC9 cell proliferation when com-
pared to ICI+YC137 (Figure 4A).
Autophagy can be pro-death [15,18] or pro-survival [17,25]. To
determine the effect of autophagy inhibition on cell death, we
measured mitochondrial membrane permeability (MMP), apopto-
sis, and necrosis after treatment with 3MA. The ICI-resistant
LY2 cells were also examined to compare their response to
BCL2+BCL-W co-inhibition and autophagy inhibition with ICI-
resistant MCF-7/LCC9 cells. While LY2 cells express low basal
levels of BCL-W, BCL2, and LC3II (not shown), cell proliferation
was significantly down-regulated following YC137, ICI, and
YC137+ICI treatment; proliferation is lowest in combination
treated cells when compared to the individual treatments (Figure
S3; ANOVA, p,0.001). Following treatment with 3MA+Y-
C137+ICI, Annexin V staining increased significantly in resistant
cells (MCF-7/LCC9; LY2) when compared to controls, cells
treated with each of 3MA, YC137, or ICI alone, or YC137+ICI
(Figure 4B; ANOVA p,0.001). MCF-7/LCC1 cells increased
relative Annexin V staining after all treatments except when
treated with 3MA alone (Figure 4B;p ,0.001).
We then determined if these effects were associated with
changes in the mitochondria. Consistent with the Annexin V
staining, MMP increased significantly in MCF-7/LCC1 cells
following treatment with ICI and YC137 alone, and after
treatment with ICI combined with YC137 and/or 3MA. In
contrast, MCF-7/LCC9 cells exhibit increased MMP only after
treatment with 3MA+YC137+ICI (Figure 4C;p ,0.001). A
decrease in PI staining, indicating a decrease in necrosis, occurred
in resistant cells only after the addition of 3MA to YC137+ICI
(Figure 4D; ANOVA p,0.001). There was no change in the
number of cells in S-phase after treatment of MCF-7/LCC9 cells
with YC137, 3MA, YC137+ICI, or 3MA+YC137+ICI (Figure
S4). Thus, the reversal of resistance can occur without the cell
cycle arrest seen in de novo sensitive cells. As expected, the number
of MCF-7/LCC1 cells undergoing S-phase decreased after
YC137+ICI and 3MA+YC137+ICI treatment (ANOVA,
p=0.016; Figure S4).
To establish further the roles of BCL-W and BCL2, we
performed similar studies in BCL-W+BCL2 siRNA co-transfected
resistant cells (MCF7/LCC9; LY2) treated with ICI and/or 3MA.
After treating the siRNA transfected MCF-7/LCC9 cells with a
combination of ICI and 3MA, we found a significant increase in
Annexin V staining in BCL-W and BCL2 siRNA co-transfected
cells (Figure 5A; ANOVA p,0.001). A significant decrease in PI
staining was also observed after BCL-W/BCL2 knockdown in
combination with ICI+3MA treatment (Figure 5B; ANOVA
p=0.05). These data imply that functional autophagy plays a
major role in influencing the decision to undergo apoptosis and/or
necrosis in antiestrogen-resistant cells.
BECN1 Mediates Key Effects of YC137, BCL-W, and BCL2
While basal BECN1 expression levels are comparable in
sensitive and resistant cells (not shown), we could not exclude
BCL2, BCL-W, and AE Resistance
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contexts. Thus, we explored the mechanistic relationship between
BCL-W, BCL2, and BECN1 using shRNA-mediated knockdown
of BECN1 in resistant cells. BECN1 shRNA effectively decreased
BECN1 protein expression (approximate 5-fold) in MCF-7/LCC9
cells (Figure 6A; p=0.029). Also, BECN1 shRNA infected MCF-
7/LCC9 cells were more sensitive to YC137 (50 nmol/L) and ICI
(500 nmol/L) than control infected cells, and cell proliferation was
down-regulated after treatment with YC137 or ICI (Figure 6B;
ANOVA, p,0.001). However, cell proliferation following
YC137+ICI treatment was significantly lower than either
treatment alone. For BECN1 knockdown combined with ICI
treatment, RI=1.23 suggests at least an additive interaction.
Unlike control infected cells, proliferation was downregulated in
BECN1 shRNA infected cells treated with YC137 or YC137+ICI
(Figure 6B; ANOVA p,0.001). Furthermore, apoptosis was
significantly increased in cells treated with YC137+ICI
(Figure 6C; ANOVA p,0.001). The level of necrosis increased
in control infected cells, and decreased in BECN1 shRNA infected
cells, when treated with YC137+ICI (Figure 6D; ANOVA
p,0.05). BECN1 knockdown, in combination with BCL2+BCL-
W co-inhibition, inhibited autophagy, restored ICI sensitivity, and
increased apoptosis (but not necrosis) in ICI treated antiestrogen-
resistant breast cancer cells. These different cell death outcomes in
sensitive and resistant cells indicate considerable plasticity in breast
cancer cell fate mechanisms in response to antiestrogens.
Figure 3. LC3II and p62/SQSTM1 expression after BCL-W and BCL2 inhibition. Whole cell lysates were subjected to Western blot analysis
with a specific LC3 or p62/SQSTM1 antibody. (A) Bars represent the mean6SE of the relative LC3II:actin ratio (normalized to empty vector controls)
for three independent experiments. Inset, a representative blot.( B) Bars represent the mean6SE of the relative p62/SQSTM1:actin ratio (normalized to
empty vector controls) for three independent experiments. Inset, a representative blot.( C) Cells were transfected with siRNA and LC3II measured by
Western blot analysis. Bars represent the mean6SE of the relative LC3II:actin ratio (normalized to empty vector controls) for three independent
experiments.
doi:10.1371/journal.pone.0008604.g003
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Antiestrogen resistance is a major limitation to improving breast
cancer survival rates and elucidating its mechanisms remains an
important challenge [26,27]. In breast tumors, BCL2 expression
measured prior to therapy correlates with ER expression and an
improved response to antiestrogens [28]. However, BCL2 levels
decrease after TAM therapy, but only in those women who obtain
clinical benefit [29]. In breast tumors, apoptosis increases after the
first 24 hr of TAM treatment but markedly decreases 3-months
later. Moreover, BCL2 expression is elevated in residual (resistant)
tumors [30]. We hypothesized that increased expression of BCL2
and/or BCL-W may play a role in antiestrogen resistance by
allowing resistant cells to evade apoptosis. We show that in the
absence of estrogen there is an increase in basal and ICI-regulated
BCL2 mRNA, protein, and promoter activity in resistant cells,
observations consistent with data showing elevated activity of two
upstream regulators of BCL2: NFkB and XBP1 [31–33]. However,
co-inhibition of BCL-W and BCL2 is required to restore ICI
sensitivity, a process that is driven by increased autophagy and
necrosis, but not apoptosis. We also show that increased autophagy
may activate necrotic cell death in resistant cells.
Figure 4. Increased apoptosis and decreased necrosis after BCL-W and BCL2 and autophagy inhibition. (A) Cells were treated with ICI,
3MA, YC137, or a combination of the three for 7-days. Bars represent the mean6SE of relative proliferation (normalized to empty vector control). (B)
Cells were treated with YC137, ICI, 3MA, YC137+ICI, or a combination of YC137, ICI, and 3MA for prior to Annexin V staining. Bars represent the
mean6SE of the relative Annexin V staining (normalized to empty vector controls) for three independent experiments. (C) Cells were treated with ICI,
3MA, YC137, or a combination prior to JC-1 staining. (D) Cells were treated with YC137, ICI, 3MA, YC137+ICI, or a combination of YC137, ICI, and 3MA
prior to PI staining. Bars represent the mean6SE of the relative PI staining (normalized to empty vector controls) for three independent experiments.
doi:10.1371/journal.pone.0008604.g004
BCL2, BCL-W, and AE Resistance
PLoS ONE | www.plosone.org 6 January 2010 | Volume 5 | Issue 1 | e8604Little is known about BCL-W expression and function in breast
cancer. Since BCL-W is overexpressed in some human colon
cancer cells [6,34] and its expression is regulated by estrogen in
cerebrocortical neuron cultures [35], we hypothesized that BCL-
W could play a role in antiestrogen resistance. BCL-W expression
is increased by ICI in both sensitive and resistant cells, suggesting
that an increased co-expression of both BCL2 and BCL-W is
required for antiestrogen resistance. Hence, the ICI-induced
increase in the expression of BCL-W alone in antiestrogen-
sensitive cells has little effect on responsiveness unless accompanied
by a concurrent increase in BCL2, as is seen in resistant cells.
Small-molecule inhibitors of proapoptotic BCL2 family mem-
bers can restore sensitivity to some therapeutic agents that induce
apoptosis [36]. Some of these compounds inhibit the proliferation
of cells that express high levels of BCL2 [37]. However, several
antiapoptotic BCL2 family members also regulate autophagy
through their interactions with BECN1 [12,38,39]. In resistant
MCF-7/LCC9 and LY2 cells, only the levels of autophagy and
necrosis increase after YC137+ICI treatment; there is no increase
in either MMP or apoptosis.
We used BCL-W and/or BCL2 siRNA to confirm the results
with YC137. As expected, BCL-W+BCL2 co-inhibition has no
effect on apoptosis in ICI treated MCF-7/LCC9 cells, whereas
both autophagy and necrosis increase. Inhibition of BCL2 and
BCL-xL decreases cellular ATP and increases necrosis (but not
apoptosis) in acinar cells hyperstimulated with CCK-8 [40].
Autophagy can also activate necrosis in apoptosis-deficient mouse
embryonic fibroblasts [41]. Increased autophagosome formation is
induced early during necrotic cell death and contributes to the
cellular destruction that occurs during necrosis in Caenorhabditis
elegans [42]. These results suggest that BCL-W+BCL2 coinhibition
can increase antiestrogen sensitivity in resistant breast cancer cells
by preferentially activating necrosis, apparently in association with
the induction of autophagy. In contrast, inhibiting autophagy in
some TAM-resistant breast cancer cells can increase apoptosis
[16].
No change occurs in the proportion of cells undergoing S-phase
after 3MA+YC137+ICI treatment. Thus, it is unlikely that
autophagy plays a major role in the cell cycle arrest effects of
antiestrogens. We also show that the inhibition of autophagy, in
combination with BCL-W+BCL2 co-inhibition in ICI treated
resistant cells, does not further reduce total cell number but shifts
programmed cell death such that apoptosis increases and necrosis
decreases. Our results strongly suggest that functional autophagy is
a central component of the cell fate decision machinery in ICI-
resistant breast cancer cells, although we cannot exclude the
possibility that autophagy also alters the kinetics of cell death.
Nonetheless, in addition to being a cell death effector mechanism,
autophagy appears to be a central component in influencing how
breast cancer cells die in response to antiestrogens.
In summary, our results show that BCL-W+BCL2 co-inhibition
restores ICI sensitivity in antiestrogen-resistant cells and increases
ICI sensitivity in antiestrogen-sensitive cells. We show that the
overexpression of BCL-W and BCL2 is linked to determining cell
fate through autophagy in ICI resistant breast cancer models
(Figure S5A). We have shown that BCL-W+BCL2 coinhibition
increases autophagy and necrosis with no effect on the extent of
apoptotic cell death (Figure S5B). These data suggest that BCL-
W and BCL2 activate apoptosis and necrosis by initially regulating
autophagy (Figure S5C). We conclude that the co-inhibition of
BCL-W and BCL2 restores sensitivity in antiestrogen-resistant
breast cancer cells by promoting an autophagy-associated increase
in necrosis. Antiestrogen sensitive cells undergo autophagy and/or
apoptosis, whereas resistant cells undergo autophagy and necrosis
when resensitized. These different cell death outcomes in sensitive
and resistant cells show the notable plasticity of cell fate
mechanisms in breast cancer. In resistant cells, resensitization to
antiestrogens can also occur without the cell cycle arrest that
accompanies cell death in de novo sensitive cells. Thus, antiestro-
gen-regulated signaling that modifies cell cycling occurs through
mechanisms independent of mitochondrial function and cell
death.
From a therapeutic perspective, these data also suggest that
broad rather than specific BCL2 family member inhibitors will
have greater clinical value and may explain the apparent lack of
activity of targeted BCL2 antisense monotherapy in clinical trials
[43]. Combination therapy with endocrine agents and broadly
active small molecule inhibitors of BCL2 family members may
delay, prevent, or reverse the acquisition of antiestrogen resistance
in breast cancer patients and lead to significant improvements in
survival.
Figure 5. BCL-W/BCL2 knockdown and autophagy inhibition
increases apoptosis and decreases necrosis. (A) MCF-7/LCC9 cells
were transfected with a combination of BCL-W and BCL2 siRNA and
treated with ICI and 3MA. Bars represent the mean6SE of the relative
Annexin V staining (normalized to empty vector controls) for three
independent experiments. (B) Bars represent the mean6SE of the
relative PI staining (normalized to empty vector controls) for three
independent experiments.
doi:10.1371/journal.pone.0008604.g005
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Cell Culture
All cells were shown to be free of Mycoplasma spp. contamination.
MCF-7/LCC1 (ER+, estrogen independent, antiestrogen-sensitive)
[19]; MCF-7/LCC9 (ER+, estrogen independent, TAM and ICI
cross-resistantvariantderived from MCF-7/LCC1cellsbyselection
against ICI) [21], and LY2 cells (ER+, estrogen independent, LY
117018, TAM, and ICI cross-resistant, MCF-7 variant derived by
selection against the Raloxifene analog LY 117018) [20] were
routinely grown in improved minimal essential medium without
phenol red and supplemented with 5% charcoal stripped calf serum
(CCS-IMEM; Biofluids). We confirmed the genetic lineage of the
three variantcell linesasbeing derived from the originalMCF-7 cell
line by DNA fingerprinting using genetic markers at nine different
loci. All cells were maintained at 37uC in a humidified incubator
with 95% air:5% CO2 atmosphere. ICI was obtained from Tocris
Bioscience (Ellisville, MO) and 3-methyladenine (3MA) from Sigma
Aldrich (St. Louis, MO). Acridine orange was obtained from EMD
Biosciences(San Diego,CA)and ethidium bromide from Invitrogen
(Carlsbad, CA). YC137 was kindly provided by Dr. York Tomita
(Georgetown University) [44].
Figure 6. BECN1 knockdown and BCL-W/BCL2 co-inhibition decreases cell proliferation through increased apoptosis in resistant
cells. (A) Whole cell lysates were subjected to Western blot analysis with a specific BECN1 monoclonal antibody. Bars represent the mean6SE of the
relative BECN1:actin ratio (normalized to control cells) for three independent experiments. (B) shRNA infected MCF-7/LCC9 cells were treated with
YC137 and/or ICI for 7-days. Bars represent the mean6SE of relative cell proliferation (normalized to EtOH treated controls) for a single representative
experiment performed in triplicate. (C) shRNA infected MCF-7/LCC9 cells were treated with YC137, ICI, or a combination of YC137 and ICI. Bars
represent the mean6SE of the relative Annexin V staining (normalized to empty vector controls) for three independent experiments. (D) Bars
represent the mean6SE of the relative PI staining (normalized to empty vector controls) for three independent experiments.
doi:10.1371/journal.pone.0008604.g006
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Total RNA was isolated using the Trizol method. For eachcDNA
sampleaqPCRreactionandastandardcurve wereestablishedusing
TaqMan Universal PCR Master Mix and the following TaqMan
primers (Applied Biosystems): BCL2=Hs00608023_m1; BCL-W
(BCL2L2)=Hs00187848_m1; RPLP0 (housekeeping gene)=
Hs99999902_m1. Each reaction (10 ml) was run in triplicate on an
ABI Prism 7900HT Sequence Detection System using the
manufacturer’s absolute quantification protocol. Expression data
for each reaction was estimated relative to expression of RPLP0.
Transient Transfection and Promoter-Reporter Assays
Cells were plated at 60,000 cells/well and maintained for 24 hr
prior to co-transfection with 0.4 mg of full length BCL2 promoter-
luciferase reporter plasmid [45] (a generous gift from Dr. Linda
Boxer, Stanford University Medical Center) and 0.004 mg of the
phRL-SV40-Renilla control plasmid containing the Renilla lucif-
erase gene (Promega, Madison, WI). Activation of the BCL2
promoter was measured using the Dual Luciferase Assay Kit
(Promega) and luminescence measured using a Lumat LB 9501
luminator (EG&G Berthold, Bundoora, Australia).
siRNA Transfection and Lentiviral shRNA Infection
Cells were plated at 100,000 cells/well and BCL2, BCL-W
(Dharmacon, Lafayette, CO), and control siRNA (Santa Cruz
Biotechnology, Santa Cruz, CA) were each diluted to 100 nM.
Transfection was performed according to Dharmacon’s protocol
using Lipofectamine 2000 (Invitrogen). Twenty-four hours after
transfection, cells were treated with ICI, 3MA, a combination of
the two, or ethanol vehicle for 48 hr. For the lentiviral infection,
cells were plated at 10,000 cells/well and allowed to incubate
for 24 hr prior to shRNA infection. BECN1 lentiviral particles
and control lentiviral particles were purchased from Dharma-
con. The infection was carried out according to the Dharmacon
SMARTvector shRNA lentiviral protocol using Polybrene
(Millipore).
Western Blotting
Cells were treated as appropriate and lysed in radioimmuno-
precipitation assay buffer [150 mmol/L NaCl, 50 mmol/L Tris
(pH 7.5), 1% Igepal CA-630, and 0.5% deoxycholate] supple-
mented with Complete Mini protease inhibitor cocktail tablets
(Roche) and 1 mmol/L sodium orthovanadate phosphatase
inhibitor (Sigma). The primary antibodies used were: mouse
monoclonal BCL2 primary antibody (1:1000; Assay Designs,
Ann Arbor, MI), rabbit monoclonal BCL-W primary antibody
( 1 : 5 0 0 ;C e l lS i g n a l i n g ,D a n v e r s ,M A ) ,r a b b i tp o l y c l o n a lL C 3 B
primary antibody (1:500; Cell Signaling), mouse monoclonal
p62/SQSTM1 primary antibody (1:500; Abcam, Cambridge,
MA) overnight. Antigen-antibody complexes were visualized
using the ECL detection system (Amersham Biosciences) and
SuperSignal Chemiluminescent Substrate (Thermoscientific).
Protein expression was quantified using densitometric analysis;
data (mean6SE) are presented as the ratio of target protein:
bactin signals.
Cell Proliferation
5,000 cells/well were treated as appropriate for 7-days.
Following treatment, cells were stained with a crystal violet
staining solution [46]. Sodium citrate buffer was added to each
well and absorbance measured at 550 nM using a microplate
reader (Biorad, Hercules, CA).
Cell Cycle, Apoptosis, Necrosis, and Autophagy
Fluorescence activated cell sorting (FACS) was performed by
the Lombardi Comprehensive Cancer Center Flow Cytometry
Shared Resource. For cell cycle analysis, cells were plated at
80,000–100,000 cells/well, treated as appropriate for 48 hr, fixed,
and analyzed by FACS. To measure apoptosis, cells were treated
for 48 hr and stained as described in the TACS Annexin V Kit
(Trevigen, Gaithersburg, MD). Necrosis was measured by
counting cells stained red by propidium iodide (PI). For
morphologic analysis of necrosis, cells were plated, treated 24 hr
later, and after a further 48 hr stained with acridine orange/
ethidium bromide solution (100 mg/ml acridine orange in
PBS:100 mg/ml ethidium bromide in PBS) and examined using
an Olympus IX-70 confocal microscope with 488 nm and 633 nm
excitation lasers.
To measure autophagy, we performed Western blot analysis to
measure LC3 cleavage and p62/SQSTM1 expression [23]. Cells
treated with 2 mg/ml tunicamycin (EMD Biosciences) for 48 hours
were the positive control for LC3 cleavage. To block functional
autophagy, we treated cells with the autophagy inhibitor 3MA, or
infected cells with lentiviral BECN1 shRNA.
Mitochondrial Membrane Permeability
Cells were treated as appropriate and stained with 100 ml of JC-
1 dye solution (Invitrogen) for 25 min at 37uC. Green fluorescence
(485 nm excitation/535 nm emission) was measured on a Wallac
Viktor2 1420 Multilabel Counter (Perkin-Elmer, Boston, MA).
Statistical Analyses
One-way ANOVA was used to determine overall significant
differences following treatment in the cell proliferation, cell cycle,
apoptosis, and MMP assays. Student’s t-test was used to determine
differences in BCL2, BCL-W, LC3, p62/SQSTM1 expression
and luciferase promoter-reporter activity. All statistical analyses
were performed using SigmaStat version 3.0. The nature of drug
interactions (synergy, antagonism, additivity) was assessed using
the Relative Index (RI) [47]. RI values were obtained by
calculating the expected cell survival (Sexp; the product of survival
obtained with drug A alone and the survival obtained with drug B
alone) and dividing this Sexp by the observed cell survival in the
presence of both drugs (Sobs). Sexp/Sobs.1.0 indicates a synergistic
interaction, ,1.0 indicates an antagonistic interaction, and =1 is
indicative of an additive interaction between the two drugs used.
Supporting Information
Figure S1 Increased basal BCL2 promoter activity in ICI/
TAM-cross-resistant MCF-7/LCC9 cells. Cells were seeded in 12-
well plates and co-transfected with BCL2 promoter-luciferase and
pCMV-Renilla constructs for 24 h prior to lysis and luminescent
detection (to examine basal promoter activity). Bars represent the
mean6SE of the relative BCL2-luciferase: Renilla luciferase
activity for a single representative experiment performed in
triplicate. p,0.003 for MCF-7/LCC9 vs. MCF-7/LCC1.
Found at: doi:10.1371/journal.pone.0008604.s001 (1.44 MB TIF)
Figure S2 Increased sensitivity to ICI 182,780 in antiestrogen-
sensitive cells. A, MCF-7/LCC1 cells were treated with the
indicated concentrations of YC137 for 5 and 7 days, at which time
cell number was determined. Points represent the mean6SE of
relative proliferation (normalized to empty vector control).
ANOVA p,0.001; p,0.05 for YC137 vs. control. B, MCF-7/
LCC1 cells were treated with ICI or a combination of YC137+ICI
for 5 days, at which time cell number was determined. Points
BCL2, BCL-W, and AE Resistance
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empty vector control). ANOVA p,0.001; p,0.001 for
YC137+ICI treated cells vs. ICI treated cells.
Found at: doi:10.1371/journal.pone.0008604.s002 (1.01 MB TIF)
Figure S3 BCL-W/BCL2 inhibition decreases cell proliferation
in ICI 182,780 treated resistant LY2 cells. Cells were treated with
ICI, YC137, or a combination of the two for 7 days to examine
cell proliferation. Bars represent the mean6SE of relative
proliferation (normalized to empty vector control). ANOVA
p,0.001; p,0.05 for treatment vs. control treated cells and for
YC137+ICI treated cells vs. YC137 and ICI.
Found at: doi:10.1371/journal.pone.0008604.s003 (0.66 MB TIF)
Figure S4 Combined autophagy inhibition and BCL-W/BCL-2
inhibition does not alter cell cycle distribution in the resistant cell
line. Cells were treated with ICI, 3MA, YC137, or a combination
for 48 h prior to ethanol fixation and FACS analysis. ANOVA
p=0.016; p,0.05 for treatment vs. control, 3MA, or YC137.
Found at: doi:10.1371/journal.pone.0008604.s004 (0.56 MB TIF)
Figure S5 BCL-W and BCL2 indirectly regulate necrosis
through the direct regulation of autophagy and apoptosis. A,
Representation of the relationship between BCL-W/BCL2
overexpression, autophagy, necrosis, and apoptosis in ICI-resistant
cells treated with ICI 182,780. B, Representation of the effect of
BCL-W/BCL2 inhibition on autophagy, necrosis, and apoptosis.
C, Representation of the effect of BCL-W/BCL2 inhibition in
combination with autophagy inhibition on autophagy, necrosis,
and apoptosis.
Found at: doi:10.1371/journal.pone.0008604.s005 (0.16 MB TIF)
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